FDA set to decide on experimental DMD treatment in early 2027

FDA has agreed to review Dyne Therapeutics' z-rostudirsen, an exon-51-skipping therapy for DMD, with a decision expected by January 2027. If approved, the treatment could be commercially available within the first months of 2027.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.